Clinical Experience of Complete Pathological Response in MSI-H and PDL1 Positive Inoperable Gastric Cancer Treated with ICIs and Chemotherapy: Two Case Reports
Year: 2024
Type: article
Study design: Case Report
Abstract: Background: During last decades, Immunotherapy (IT) has become the gold standard treatment of many types of cancers.In gastrointestinal (GI) cancers, predictive factors of response to IT are high microsatellite instability (MSI-H) and programmed death ligand 1 (PDL1) expression.On the basis of the results from the phase 3 Checkmate 649, Nivolumab (anti-PD1) and chemotherapy (CT) is the new first line chemotherapy for advanced or metastatic gastric cancer (HER2-negative, PD-L1 CPS ≥5.Case summary: Herein, we describe two clinical cases of patients affected by advanced gastric cancer (HER2-negative, PD-L1 CPS ≥5, MSI-H), treated with immune checkpoint inhibitor (ICI) and CT who reached pathological complete response.Conclusion: MSI-H is a strong predictor of response to IT in GI cancers, also in the neoadjuvant/perioperative gastric cancer setting.We attend for confirmation by phase II infinity trial, maybe a non operative management is possible also for gastric cancer.
Source: Annals of Case Reports
Authors: Lucchetti Jessica, Di Giacomo Emanuela, Polito Mariam Grazia, Nitti Daniele, Angotti Lorenzo, Lo Prinzi Federica, Barnini Giulia, Galbato Muscio Luca, Pezzola Giorgia, Di Lascio Claudia, Vincenzi Bruno, Tonini Giuseppe
Institution: Università Campus Bio-Medico
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4408078794